Ibrutinib CAS NO.936563-96-1

Elutinib property Melting point 153-158 ° C Boiling point 715.0 ± 60.0 ° C (Predicted) Density 1.34 Storage condition -20 ° C Solubility SolubleinDMSO (uptoatleast25mg/ml) Acid dissociation constant (pKa) 4.09 ± 0.30 (Predicted) Morphology Solid color Whiteoroff white stability Stablefor1yearfromdateofpurchaseasupplied.SolutionsinDMSOmayrestoredat-20 ° Cforupto3months.InChIKeyXYFPWWZEPKGCCK-GOSISDBHSA-NSMI LESC (N1CCC [C @ @ H] (N2C3C (C (C4=CC=C (OC5=CC=CC=C5)) C=C4)=N2)=C (N) N=CN=3) C1) (=O) C=CCAS database 936563-96-1 Usage and synthesis method of Irutinib Irutinib is a Bruton Tyrosine kinase (BTK) inhibitor, which is used to treat Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non Hodgkin lymphoma, which is difficult to cure and easy to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Irutinib can target BTK, which is essential for the formation, differentiation, information transmission, and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibiting the proliferation and survival of tumor cells; After oral administration, the absorption is rapid, reaching the maximum blood drug concentration within 1-2 hours. The adverse reactions belong to level 1 or 2, and will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the US Food and Drug Administration (FDA) accelerated the approval of Pharmacyclics and Johnson&Johnson's Imbruvica (commonly known as Ibrutinib) for the treatment of a rare invasive blood cancer - mantle cell lymphoma (MCL). Ibrutinib is an oral first new drug of Bruton Tyrosine kinase (BTK) inhibitor. It was granted the drug qualification of breakthrough Sex therapy by FDA in February 2013, and was approved as a therapeutic drug for MCL and CLL on November 13, 2013 and February 12, 2014, respectively. The drug selectively covalently binds to the cysteine residue (Cys-481) at the Active site of the target protein Btk, and Irreversible process inhibits BTK, thus effectively preventing the tumor from migrating from B Cell migration to the lymphoid tissue adapted to the tumor growth environment. The above information was edited and organized by Xiaonan from Chemicalbook.

Elutinib property Melting point 153-158 ° C Boiling point 715.0 ± 60.0 ° C (Predicted) Density 1.34 Storage condition -20 ° C Solubility SolubleinDMSO (uptoatleast25mg/ml) Acid dissociation constant (pKa) 4.09 ± 0.30 (Predicted) Morphology Solid color Whiteoroff white stability Stablefor1yearfromdateofpurchaseasupplied.SolutionsinDMSOmayrestoredat-20 ° Cforupto3months.InChIKeyXYFPWWZEPKGCCK-GOSISDBHSA-NSMI LESC (N1CCC [C @ @ H] (N2C3C (C (C4=CC=C (OC5=CC=CC=C5)) C=C4)=N2)=C (N) N=CN=3) C1) (=O) C=CCAS database 936563-96-1 Usage and synthesis method of Irutinib Irutinib is a Bruton Tyrosine kinase (BTK) inhibitor, which is used to treat Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non Hodgkin lymphoma, which is difficult to cure and easy to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Irutinib can target BTK, which is essential for the formation, differentiation, information transmission, and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibiting the proliferation and survival of tumor cells; After oral administration, the absorption is rapid, reaching the maximum blood drug concentration within 1-2 hours. The adverse reactions belong to level 1 or 2, and will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the US Food and Drug Administration (FDA) accelerated the approval of Pharmacyclics and Johnson&Johnson's Imbruvica (commonly known as Ibrutinib) for the treatment of a rare invasive blood cancer - mantle cell lymphoma (MCL). Ibrutinib is an oral first new drug of Bruton Tyrosine kinase (BTK) inhibitor. It was granted the drug qualification of breakthrough Sex therapy by FDA in February 2013, and was approved as a therapeutic drug for MCL and CLL on November 13, 2013 and February 12, 2014, respectively. The drug selectively covalently binds to the cysteine residue (Cys-481) at the Active site of the target protein Btk, and Irreversible process inhibits BTK, thus effectively preventing the tumor from migrating from B Cell migration to the lymphoid tissue adapted to the tumor growth environment. The above information was edited and organized by Xiaonan from Chemicalbook.